2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian canc...
2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian cancerpatients after primary treatment; A phase I clinical trial
About this item
Full title
Author / Creator
Publisher
Kidlington: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
Introduction/BackgroundDCP-001 is a cell-based relapse vaccine developed to prevent disease recurrence following primary treatment. Trials in patients with acute myeloid leukemia have shown DCP-001 to be well-tolerated and interim results of an ongoing phase II study (ADVANCE II) revealed durable clinical responses. Interestingly, the tumor-associa...
Alternative Titles
Full title
2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian cancerpatients after primary treatment; A phase I clinical trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2728874942
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2728874942
Other Identifiers
ISSN
1048-891X
E-ISSN
1525-1438
DOI
10.1136/ijgc-2022-ESGO.648
